Pharmaceutical intermediates
Bedaquiline Fumarate Intermediates
3 pharmaceutical intermediates for Bedaquiline Fumarate. Indication: Multidrug-resistant tuberculosis.
About Bedaquiline Fumarate
- Originator
- Janssen Therapeutics Div Janssen Products Lp
- Indication
- Multidrug-resistant tuberculosis
- Approved Date
- 12/28/2012
- DS/DP
- 12/01/2016
Available intermediates
3 intermediates currently listed for Bedaquiline Fumarate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-Dimethylamino-1-(naphthalen-1-yl)propan-1-one hydrochloride | 5409-58-5 | / | / |
| 3-Benzyl-6-bromo-2-methoxyquinoline | 654655-69-3 | / | / |
| 4-hydroxydinaphtho[2,1 -d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide compound with (1R,2S)-1-(6-bromo-2-methoxyquinolin -3-yl)-4- (dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol(1:1) | 916329-20-9 | / | / |
Building toward Bedaquiline Fumarate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →